- African plum tree
For Patients & Caregivers
Bottom Line: Pygeum africanum relieves the symptoms of benign prostatic hypertrophy (BPH). Its effects following long-term use are not known.
Several compounds present in Pygeum africanum reduce inflammation by stopping the production of prostaglandins, indicators of inflammation in the body. These compounds also work synergistically to reduce levels of testosterone in the prostate. This is why Pygeum is used to treat benign prostatic hypertrophy (BPH), in which growth of the prostate is enhanced by testosterone.
- To treat benign prostatic hypertrophy (BPH)
Several clinical trials show that Pygeum africanum is effective in improving urination symptoms in patients with BPH, but the long-term effectiveness and safety of this herb are not known.
- To reduce inflammation
Laboratory studies show that chemicals in pygeum have anti-inflammatory effects, but human data are lacking.
- To improve sexual performance
No scientific evidence supports this use.
Benign prostatic hypertrophy (BPH):
A meta-analysis, which is a systematic review of all of the clinical trials that have been performed with a therapy, looked at the use of Pygeum africanum to treat BPH. In 6 of 18 randomized controlled trials that were analyzed, Pygeum africanum was more effective at relieving urinary symptoms than a placebo pill, with no major side effects. For example, the need to wake up at night to urinate was reduced by 19% and urine flow increased by 23%.
For Healthcare Professionals
Derived from the tree bark, pygeum extracts are traditionally used to manage lower urinary tract symptoms associated with benign prostatic hypertrophy (BPH) (1). In vitro and in vivo studies indicate that pygeum extracts have bactericidal and fungicidal activity (2), antagonize the androgen receptor (3), and have antiproliferative and apoptotic effects against prostate cancer cells (4)(5)(6)(7). Clinical studies suggest effectiveness of pygeum (8)(9)(10)(11) and formulations containing pygeum and other herbs (12) to improve urinary symptoms associated with BPH. However, additional larger studies are needed to demonstrate usefulness of pygeum compared with standard treatments in current use for BPH.
Pygeum antagonizes 5-lipoxygenase metabolite production, and this action may contribute to its anti-inflammatory effects (15). Antimicrobial effects have been linked to inhibition of IL-7 mRNA expression (2).
The isolated compounds atraric acid and N-butylbenzene-sulfonamide were identified as androgen receptor antagonists, which play an important role in the development of prostate diseases (16).
Antiproliferative and apoptotic effects of pygeum on prostate fibroblasts and myofibroblasts are due to downregulation of transforming growth factor B1 (TGFB1) and inhibition of fibroblast growth factor 2 (FGF2)-specific signaling (6).
Ishani A, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000;109:654-64.
A total of 18 randomized controlled trials involving 1,562 men were analyzed. Seventeen of the studies were double-blind. The mean study duration was 64 days. Compared with placebo in 6 studies, Pygeum africanum provided a moderately large improvement in the combined outcome of urologic symptoms and flow measures. Nocturia was reduced by 19% and residual urine volume by 24%; peak urine flow increased by 23%. Adverse effects due to Pygeum africanum were similar to placebo.